查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1855928

2025年全球分子肿瘤学板解决方案市场报告

Molecular Tumor Board Solutions Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，分子肿瘤委员会解决方案市场规模快速成长，从2024年的13.4亿美元成长到2025年的15.3亿美元，复合年增长率达13.9%。这一成长趋势的驱动因素包括基因组分析技术的日益普及、精准肿瘤学需求的成长、分子诊断意识的提高、癌症研究倡议的拓展以及医院与生物技术公司之间合作的加强。

预计未来几年分子肿瘤委员会解决方案市场将快速成长，到2029年市场规模将达到25.3亿美元，复合年增长率（CAGR）为13.5%。预测期内的成长主要受以下因素驱动：对多学科肿瘤委员会的需求不断增长、云端基础的分子数据平台不断扩展、基因组检测监管支持力度加大、以患者为中心的肿瘤治疗日益受到重视以及癌症发病率不断上升。预测期内的主要趋势包括：基因测序工具的进步、分子解决方案研发投入的增加、临床决策支援软体的创新、数据分析和视觉化技术的改进以及机器学习在治疗建议中的应用。

分子肿瘤委员会解决方案是先进的平台，旨在透过整合详细的患者特异性分子和基因组信息，协助多学科临床团队分析癌症病例。这些解决方案能够识别可操作的基因变化、评估标靶治疗方案并审查相关的临床试验，从而促进知情且个人化的治疗决策。

分子肿瘤委员会解决方案的主要组成部分是软体和服务。软体包括数位平台和应用程序，用于整合患者数据、分析基因谱并提供癌症治疗提案。这些解决方案可部署在本地或云端基础系统，应用于临床决策支援、基因组资料解读和病患管理等领域。主要最终用户包括医院、癌症中心、研究机构和其他医疗机构。

美国在2025年春季突然提高关税，由此引发的贸易摩擦对医疗保健产业造成了严重衝击，尤其对关键医疗设备、诊断试剂和药品的供应造成了严重影响。医院和医疗机构面临进口手术器械、影像设备以及注射器、导管等耗材成本不断上涨的困境。这些成本的增加加剧了医疗预算的紧张，导致一些医疗机构必须推迟设备升级或将成本转嫁给患者。此外，原料和零件的关税也阻碍了必需药品和医疗设备的生产，造成供应链瓶颈。为了应对这项挑战，医疗产业正在积极调整筹资策略，尽可能地促进本地生产，并呼吁对紧急医疗产品实施关税豁免。

本研究报告是商业研究公司（The Business Research Company）最新系列报告的一部分，提供分子肿瘤板解决方案市场统计数据，包括全球市场规模、区域份额、竞争对手及其市场份额、详细的市场细分、市场趋势和商机，以及您在分子肿瘤板解决方案行业取得成功所需的数据。本分子肿瘤板解决方案市场研究报告对该行业的现状和未来发展趋势进行了详细分析，为您提供所需的一切观点。

预计未来几年，癌症发生率的不断上升将推动分子肿瘤委员会解决方案市场的成长。癌症是一组以体内异常细胞不受控制地生长和扩散为特征的疾病。癌症发生率的上升归因于不良饮食、吸烟、缺乏运动和过度饮酒等生活方式因素。分子肿瘤委员会解决方案透过提供专家对患者基因组和临床数据的多学科审查，为癌症治疗提供支持，并帮助制定个人化的治疗方案。透过整合分子谱分析和人工智慧主导的洞察，这些解决方案可以增强临床决策，提高治疗的准确性和患者预后。例如，英国国家医疗服务体系 (NHS) 在 2024 年 10 月报告称，2022 年新增癌症病例增加了 5%，从 2021 年的 329,664 例增加到 346,217 例，平均每天新增 948 例。因此，癌症发生率的上升正在推动分子肿瘤委员会解决方案市场的成长。

分子肿瘤活检解决方案市场的企业正致力于开发创新的分子谱分析检测方法，以提高癌症诊断和治疗方案製定的准确性和有效性。分子谱分析检测透过分析肿瘤的​​遗传和分子特征来指导个体化治疗决策。例如，专注于精准肿瘤学的美国生物技术公司Guardant Health Inc.于2025年4月推出了Guardant360 Tissue，这是一款先进的肿瘤组织分子谱分析检测。此检测整合了全面的多组学分析，包括DNA、RNA、人工智慧驱动的PD-L1以及全基因组甲基化数据。 Guardant360 Tissue基于Guardant Infinity智慧液态切片平台，能够提供更全面的癌症信息，从而实现更精准的肿瘤分类和亚型分析。检测结果可在两週内获得，合格的患者可享有联邦医疗保险（Medicare）的报销。该检测旨在透过提供有价值的资讯来增强精准肿瘤学，从而指导包括PARP抑制剂和免疫疗法在内的各种治疗决策。

2024年9月，美国医疗保健公司LabCorp Holdings Inc.以2.375亿美元收购了BioReference Health LLC。此次收购使LabCorp能够扩展其检测服务网络，并增加重点地区患者、医生和客户获得临床检测的机会。 BioReference Health LLC专注于分子肿瘤委员会解决方案，提供全面的基因组检测和广泛的诊断测试。

分子肿瘤委员会解决方案市场包括营业单位透过向医疗服务提供者和患者提供专业临床咨询、个人化治疗提案和决策支援服务而产生的收入。市场价值还包括服务提供者销售的或包含在其服务产品中的相关商品的价值。仅包括在营业单位间交易或销售给最终消费者的商品和服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球分子肿瘤委员会解决方案：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 终端用户产业分析
  • 全球分子肿瘤委员会解决方案市场：成长率分析
  • 全球分子肿瘤委员会解决方案市场表现：规模与成长，2019-2024年
  • 全球分子肿瘤委员会解决方案市场预测：规模与成长，2024-2029年，2034年预测
  • 全球分子肿瘤委员会解决方案：潜在市场规模 (TAM)

第六章 市场细分

  • 全球分子肿瘤板解决方案市场：按组件划分，实际值和预测值，2019-2024年、2024-2029年预测值、2034年预测值
  • 软体
  • 服务
  • 全球分子肿瘤板解决方案市场：依部署模式划分，实际值及预测值，2019-2024年、2024-2029年预测值、2034年预测值
  • 本地部署
  • 云端基础的
  • 全球分子肿瘤板解决方案市场：按应用领域划分，实际结果与预测，2019-2024年、2024-2029年预测、2034年预测
  • 临床决策支持
  • 基因组数据解读
  • 病患管理
  • 其他用途
  • 全球分子肿瘤板解决方案市场：依最终用户划分，实际值和预测值，2019-2024年、2024-2029年预测值、2034年预测值
  • 医院
  • 癌症中心
  • 研究所
  • 其他最终用户
  • 全球分子肿瘤学板解决方案市场：按软体、类型、实际值和预测值细分，2019-2024年、2024-2029年预测值、2034年预测值
  • 临床决策支持
  • 数据分析
  • 彙报和可视化
  • 整合平台
  • 全球分子肿瘤委员会解决方案市场：按服务、类型、实际值和预测值细分，2019-2024年、2024-2029年预测值、2034年预测值
  • 咨询
  • 执行
  • 培训和支持
  • 维护和升级

第七章 区域和国家分析

  • 全球分子肿瘤学板解决方案市场：按地区划分，实际结果和预测，2019-2024年、2024-2029年预测、2034年预测
  • 全球分子肿瘤板解决方案市场：国家/地区、绩效及预测，2019-2024年、2024-2029年预测、2034年预测

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章：西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章：俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

  • 分子肿瘤委员会解决方案市场：竞争格局
  • 分子肿瘤委员会解决方案市场：公司简介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • Koninklijke Philips NV Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Novogene Co. Ltd.
  • QIAGEN NV
  • Myriad Genetics Inc.
  • BGI Genomics Co. Ltd.
  • Guardant Health Inc.
  • Caris Life Sciences Inc.
  • Mayo Clinic Laboratories
  • Sectra AB
  • GenomOncology LLC
  • MedGenome Labs Ltd.
  • Burning Rock Biotech Limited
  • NantHealth Inc.
  • SOPHiA GENETICS SA
  • Variantyx Inc.
  • Baylor Genetics

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

  • 2029年分子肿瘤委员会解决方案市场：提供新机会的国家
  • 2029年分子肿瘤委员会解决方案市场：提供新机会的细分市场
  • 2029年分子肿瘤委员会解决方案市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章附录

简介目录
Product Code: r38580

Molecular tumor board solutions are advanced platforms designed to support multidisciplinary clinical teams in analyzing cancer cases by integrating detailed patient-specific molecular and genomic information. These solutions enable the identification of actionable genetic mutations, evaluation of targeted therapy options, and discussion of relevant clinical trials, thereby facilitating informed and personalized treatment decisions.

The primary components of molecular tumor board solutions are software and services. Software includes digital platforms and applications that integrate patient data, analyze genetic profiles, and provide treatment recommendations for cancer care. These solutions can be deployed via on-premises or cloud-based systems and are applied in areas such as clinical decision support, genomic data interpretation, and patient management. Key end users include hospitals, cancer centers, research institutes, and other healthcare organizations.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The molecular tumor board solutions market research report is one of a series of new reports from The Business Research Company that provides molecular tumor board solutions market statistics, including molecular tumor board solutions industry global market size, regional shares, competitors with a molecular tumor board solutions market share, detailed molecular tumor board solutions market segments, market trends and opportunities, and any further data you may need to thrive in the molecular tumor board solutions industry. This molecular tumor board solutions market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The molecular tumor board solutions market size has grown rapidly in recent years. It will grow from $1.34 billion in 2024 to $1.53 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth during the historic period was driven by increasing adoption of genomic profiling, rising demand for precision oncology, growing awareness of molecular diagnostics, expansion of cancer research initiatives, and increasing collaborations between hospitals and biotech firms.

The molecular tumor board solutions market size is expected to see rapid growth in the next few years. It will grow to $2.53 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth during the forecast period is fueled by rising demand for multidisciplinary tumor boards, expansion of cloud-based molecular data platforms, increasing regulatory support for genomic testing, greater focus on patient-centric oncology care, and rising incidence of cancer cases. The primary trends in the forecast period include advancements in genomic sequencing tools, increased investment in research and development for molecular solutions, innovation in clinical decision support software, improvements in data analytics and visualization, and integration of machine learning for treatment recommendations.

The increasing prevalence of cancer is expected to drive the growth of the molecular tumor board solutions market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells in the body. The rising incidence of cancer can be attributed to lifestyle factors such as poor diet, smoking, lack of physical activity, and excessive alcohol consumption. Molecular tumor board solutions support cancer care by offering expert, multidisciplinary reviews of patients' genomic and clinical data, helping to develop personalized treatment plans. By integrating molecular profiling with AI-driven insights, these solutions enhance clinical decision-making, improving treatment precision and patient outcomes. For example, in October 2024, the National Health Service (NHS) reported a 5% increase in new cancer diagnoses, from 329,664 cases in 2021 to 346,217 in 2022, averaging 948 new cases per day. As a result, the rising cancer prevalence is contributing to the growth of the molecular tumor board solutions market.

Companies in the molecular tumor board solutions market are focusing on developing innovative molecular profiling tests to improve the accuracy and effectiveness of cancer diagnostics and treatment planning. Molecular profiling tests analyze a tumor's genetic and molecular features to guide personalized treatment decisions. For example, in April 2025, Guardant Health Inc., a US-based biotechnology company specializing in precision oncology, launched Guardant360 Tissue, an advanced molecular profiling test for tumor tissue. This test incorporates comprehensive multiomic analysis, including DNA, RNA, AI-powered PD-L1, and genome-wide methylation data. Powered by the Guardant Infinity smart liquid biopsy platform, Guardant360 Tissue offers a more complete view of cancer, enabling more accurate tumor classification and subtyping. Results are delivered in less than two weeks, and the test is covered by Medicare for eligible patients. It aims to enhance precision oncology by providing valuable insights to guide treatment decisions, including therapies such as PARP inhibitors and immunotherapies.

In September 2024, Labcorp Holdings Inc., a US-based healthcare company, acquired BioReference Health LLC for $237.5 million. This acquisition enables Labcorp to expand its laboratory services network and broaden access to clinical testing for patients, physicians, and customers in key regions. BioReference Health LLC specializes in molecular tumor board solutions, offering comprehensive genomic testing and a wide range of diagnostic tests.

Major players in the molecular tumor board solutions market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Koninklijke Philips N.V., Illumina Inc., Novogene Co. Ltd., QIAGEN N.V., Myriad Genetics Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Caris Life Sciences Inc., Mayo Clinic Laboratories, Sectra AB, GenomOncology LLC, MedGenome Labs Ltd., Burning Rock Biotech Limited, NantHealth Inc., SOPHiA GENETICS SA, Variantyx Inc., Baylor Genetics, Molecular Health GmbH, PierianDx Inc., Oncompass Medicine, and CureMatch Inc.

North America was the largest region in the molecular tumor board solutions market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in molecular tumor board solutions report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the molecular tumor board solutions market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The molecular tumor board solutions market includes revenues earned by entities through providing expert clinical consultations, personalized treatment recommendations, and decision-support services to healthcare providers and patients. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Molecular Tumor Board Solutions Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on molecular tumor board solutions market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for molecular tumor board solutions ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The molecular tumor board solutions market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Component: Software; Services
  • 2) By Deployment Mode: On-Premises; Cloud-Based
  • 3) By Application: Clinical Decision Support; Genomic Data Interpretation; Patient Management; Other Applications
  • 4) By End-User: Hospitals; Cancer Centers; Research Institutes; Other End-Users
  • Subsegments:
  • 1) By Software: Clinical Decision Support; Data Analytics; Reporting And Visualization; Integration Platforms
  • 2) By Services: Consulting; Implementation; Training And Support; Maintenance And Upgrades
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Siemens Healthineers AG; Koninklijke Philips N.V.; Illumina Inc.; Novogene Co. Ltd.; QIAGEN N.V.; Myriad Genetics Inc.; BGI Genomics Co. Ltd.; Guardant Health Inc.; Caris Life Sciences Inc.; Mayo Clinic Laboratories; Sectra AB; GenomOncology LLC; MedGenome Labs Ltd.; Burning Rock Biotech Limited; NantHealth Inc.; SOPHiA GENETICS SA; Variantyx Inc.; Baylor Genetics; Molecular Health GmbH; PierianDx Inc.; Oncompass Medicine; CureMatch Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Molecular Tumor Board Solutions Market Characteristics

3. Molecular Tumor Board Solutions Market Trends And Strategies

4. Molecular Tumor Board Solutions Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Molecular Tumor Board Solutions Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Molecular Tumor Board Solutions PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Molecular Tumor Board Solutions Market Growth Rate Analysis
  • 5.4. Global Molecular Tumor Board Solutions Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Molecular Tumor Board Solutions Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Molecular Tumor Board Solutions Total Addressable Market (TAM)

6. Molecular Tumor Board Solutions Market Segmentation

  • 6.1. Global Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Software
  • Services
  • 6.2. Global Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • On-Premises
  • Cloud-Based
  • 6.3. Global Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinical Decision Support
  • Genomic Data Interpretation
  • Patient Management
  • Other Applications
  • 6.4. Global Molecular Tumor Board Solutions Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Cancer Centers
  • Research Institutes
  • Other End-Users
  • 6.5. Global Molecular Tumor Board Solutions Market, Sub-Segmentation Of Software, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinical Decision Support
  • Data Analytics
  • Reporting And Visualization
  • Integration Platforms
  • 6.6. Global Molecular Tumor Board Solutions Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Consulting
  • Implementation
  • Training And Support
  • Maintenance And Upgrades

7. Molecular Tumor Board Solutions Market Regional And Country Analysis

  • 7.1. Global Molecular Tumor Board Solutions Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Molecular Tumor Board Solutions Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Molecular Tumor Board Solutions Market

  • 8.1. Asia-Pacific Molecular Tumor Board Solutions Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Molecular Tumor Board Solutions Market

  • 9.1. China Molecular Tumor Board Solutions Market Overview
  • 9.2. China Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Molecular Tumor Board Solutions Market

  • 10.1. India Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Molecular Tumor Board Solutions Market

  • 11.1. Japan Molecular Tumor Board Solutions Market Overview
  • 11.2. Japan Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Molecular Tumor Board Solutions Market

  • 12.1. Australia Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Molecular Tumor Board Solutions Market

  • 13.1. Indonesia Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Molecular Tumor Board Solutions Market

  • 14.1. South Korea Molecular Tumor Board Solutions Market Overview
  • 14.2. South Korea Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Molecular Tumor Board Solutions Market

  • 15.1. Western Europe Molecular Tumor Board Solutions Market Overview
  • 15.2. Western Europe Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Molecular Tumor Board Solutions Market

  • 16.1. UK Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Molecular Tumor Board Solutions Market

  • 17.1. Germany Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Molecular Tumor Board Solutions Market

  • 18.1. France Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Molecular Tumor Board Solutions Market

  • 19.1. Italy Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Molecular Tumor Board Solutions Market

  • 20.1. Spain Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Molecular Tumor Board Solutions Market

  • 21.1. Eastern Europe Molecular Tumor Board Solutions Market Overview
  • 21.2. Eastern Europe Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Molecular Tumor Board Solutions Market

  • 22.1. Russia Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Molecular Tumor Board Solutions Market

  • 23.1. North America Molecular Tumor Board Solutions Market Overview
  • 23.2. North America Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Molecular Tumor Board Solutions Market

  • 24.1. USA Molecular Tumor Board Solutions Market Overview
  • 24.2. USA Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Molecular Tumor Board Solutions Market

  • 25.1. Canada Molecular Tumor Board Solutions Market Overview
  • 25.2. Canada Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Molecular Tumor Board Solutions Market

  • 26.1. South America Molecular Tumor Board Solutions Market Overview
  • 26.2. South America Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Molecular Tumor Board Solutions Market

  • 27.1. Brazil Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Molecular Tumor Board Solutions Market

  • 28.1. Middle East Molecular Tumor Board Solutions Market Overview
  • 28.2. Middle East Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Molecular Tumor Board Solutions Market

  • 29.1. Africa Molecular Tumor Board Solutions Market Overview
  • 29.2. Africa Molecular Tumor Board Solutions Market, Segmentation By Component, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Molecular Tumor Board Solutions Market, Segmentation By Deployment Mode, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Molecular Tumor Board Solutions Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Molecular Tumor Board Solutions Market Competitive Landscape And Company Profiles

  • 30.1. Molecular Tumor Board Solutions Market Competitive Landscape
  • 30.2. Molecular Tumor Board Solutions Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Koninklijke Philips N.V. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Molecular Tumor Board Solutions Market Other Major And Innovative Companies

  • 31.1. Novogene Co. Ltd.
  • 31.2. QIAGEN N.V.
  • 31.3. Myriad Genetics Inc.
  • 31.4. BGI Genomics Co. Ltd.
  • 31.5. Guardant Health Inc.
  • 31.6. Caris Life Sciences Inc.
  • 31.7. Mayo Clinic Laboratories
  • 31.8. Sectra AB
  • 31.9. GenomOncology LLC
  • 31.10. MedGenome Labs Ltd.
  • 31.11. Burning Rock Biotech Limited
  • 31.12. NantHealth Inc.
  • 31.13. SOPHiA GENETICS SA
  • 31.14. Variantyx Inc.
  • 31.15. Baylor Genetics

32. Global Molecular Tumor Board Solutions Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Molecular Tumor Board Solutions Market

34. Recent Developments In The Molecular Tumor Board Solutions Market

35. Molecular Tumor Board Solutions Market High Potential Countries, Segments and Strategies

  • 35.1 Molecular Tumor Board Solutions Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Molecular Tumor Board Solutions Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Molecular Tumor Board Solutions Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer